Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Forteo

Executive Summary

Company is expecting an FDA-483 inspection report at the end of March following an ongoing pre-approval inspection of Building 358 in Indianapolis. Because the inspection closely follows a warning letter related to a pre-approval inspection for Zyprexa IM, global process changes have yet to be implemented, Lilly said (1"The Pink Sheet" March 12, p. 26). The firm continues to expect a launch for the osteoporosis drug Forteo (teriparatide) during the fourth quarter. A recent inspection of a Lilly plant in Puerto Rico resulted in few observations and no 483, the company added
Advertisement

Related Content

Zyprexa IM Manufacturing Issues To Be Discussed By FDA, Lilly March 15
Zyprexa IM Manufacturing Issues To Be Discussed By FDA, Lilly March 15
Advertisement
UsernamePublicRestriction

Register

PS037558

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel